SuperworthPERRIGO PRGO
- Market cap
- $2.2B
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 0.5×
- EV/EBIT
- 3.7×
- Revenue, 12 months
- $4.1B
- −4% on a year ago
- Net margin
- −41.9%
- Free cash flow yield
- 5.4%
PERRIGO trades at 0.5× sales. Its trailing earnings are negative, so it has no PE. Revenue was $4.1B over the last twelve months, down 4% on a year earlier with a −42% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $1.1B+2% | $1.2B+0% | $1.1B−8% | $1.1B−11% | $1.1B−3% | $1.1B−2% | $1B−4% | $1.1B−1% | $1B−4% | $1.1B−3% | $969.2M−7% | $1B−3% | |
| Cost of revenue | $712.6M−3% | $729.6M−6% | $724.4M−6% | $670.8M−12% | $683.1M−4% | $752.4M+3% | $651.6M−10% | $693.4M+3% | $666.2M−3% | $747.4M−1% | $643.7M−1% | $708.9M+2% |
| Gross profit | $411.2M+13% | $427.3M+12% | $357.7M−14% | $394.7M−8% | $404.4M−2% | $385.9M−10% | $392.3M+10% | $362.9M−8% | $377.1M−7% | $362.2M−6% | $325.5M−17% | $313.9M−14% |
| R&D | $29.6M−1% | $29.6M−9% | $29M−7% | $29.4M−9% | $26M−12% | $27.8M−6% | $26.7M−8% | $22M−25% | $24.9M−4% | $21.8M−22% | $24.6M−8% | $23.7M+8% |
| SG&A | $276.2M+10% | $281.3M+0% | $280.7M−7% | $276.2M−9% | $246.3M−11% | $211.5M−25% | $258.4M−8% | $249.5M−10% | $221.5M−10% | $233.1M+10% | $244.7M−5% | $229.5M−8% |
| $62.1M+88% | −$15.6M | −$55.2M | −$26.5M | $80.4M+30% | $114.2M | $46.9M | $45.4M | $72.6M−10% | −$1.3B | −$372.3M | $23.5M−48% | |
| Interest expense | $43.5M+6% | $42.7M+4% | $43M−2% | $44.1M+0% | $57.6M+32% | $43.1M+1% | $39M−9% | $39.6M−10% | $40.6M−30% | $43.3M+1% | $40.8M+5% | $38.4M−3% |
| Pre-tax income | $19.2M | −$54.3M+280% | −$98.6M | −$74M | $21.8M+14% | $70M | $8.3M | $3.2M | $22.4M+3% | −$1.3B | −$408.5M | $105.4M+3194% |
| $3.8M−92% | −$26.6M+1563% | −$102.7M | $31.7M+133% | $39.4M+937% | $111.5M | $8.2M | $3.7M−88% | $9.7M−75% | $82.9M−26% | −$18.7M | $16.9M+357% | |
| Net income | $14.2M | −$32.3M+36% | $2M | −$108.4M | −$21M | −$44.5M+38% | −$6.4M | −$8.4M−92% | $7.5M | −$1.4B+3087% | −$398.6M+6128% | $74.5M |
| $0.10 | −$0.24+33% | $0.01 | −$0.79 | −$0.15 | −$0.32+33% | −$0.05 | −$0.06−92% | $0.05 | −$10.17+3078% | −$2.87+5640% | $0.53 | |
| 136.9M+2% | 135.6M+1% | 137.6M+2% | 137.1M+0% | 137.5M+0% | 137.7M+2% | 137.7M+0% | 138.2M+1% | 138.9M+1% | 139.4M+1% | 138.7M+1% | 139.6M+1% |
Cost of revenue: Q1 FY13: 6 months less the 3 months printed beside them.
R&D: Q1 FY13: 6 months less the 3 months printed beside them.
SG&A: Q1 FY13: 6 months less the 3 months printed beside them.
Operating income: Q1 FY13: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY13: 6 months less the 3 months printed beside them.
Income tax: Q1 FY13: 6 months less the 3 months printed beside them.
EPS, diluted: 10 periods, Q1 FY13 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY13: share-days: the 6-month average less the second quarter's. Q4 FY15: a loss quarter: its basic count, share-days: the 6-month average less the 3-month, weighted by days. Q4 FY21: share-days: the 12-month average less the 9-month, weighted by days. 4 periods, Q4 FY22 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest PERRIGO's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| PRGOPERRIGO | $2.2B | n/m | 50.1× | 0.5× | −4% | −41.9% | |
| PBHPrestige Consumer Healthcare | $2.3B | 13.4× | 15.3× | 2.0× | −1% | 15.6% | |
| HRMYHarmony Biosciences | $2.1B | 11.7× | 13.8× | 2.2× | +24% | 18.9% | |
| NRIXNurix Therapeutics | $2.8B | 11.0× | 10.8× | 3.9× | n/m | 42.0% | |
| ANIPANI Pharmaceuticals | $1.7B | 15.4× | 60.6× | 1.7× | +31% | 11.1% | |
| PAHCPhibro Animal Health | $1.6B | 15.9× | 21.5× | 1.0× | +17% | 6.6% | |
| ANABAnaptysbio | $1.5B | 10.7× | 100.0× | n/m | n/m | n/m | |
| PCRXPacira BioSciences | $1.5B | 104× | 65.6× | 1.9× | +6% | 2.0% | |
| OGNOrganon | $3.6B | 17.9× | 5.9× | 0.6× | −2% | 3.4% | |
| LQDALiquidia | $3.8B | 30.7× | 53.6× | 8.5× | n/m | 30.7% | |
| ARQTArcutis Biotherapeutics | $3.9B | 142× | 115× | 8.5× | +76% | 6.1% | |
| Peer median | $2.2B | 15.7× | 37.5× | 2.0× | +17% | 11.1% |
Investors who own it
Investors we follow who held PERRIGO at the end of Jun 30, 2026, from their 13F filings.
- Lee AinslieMaverick Capital0.0% of portfolionew
More on PERRIGO
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .